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Abstract
Background: The X-ACT study aimed to examine the effect of omalizumab treat-
ment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with
angioedema refractory to high doses of H1-antihistamines.
Methods: In X-ACT, a phase III, double-blind, placebo-controlled study, CSU
patients (18-75 years) with ≥4 angioedema episodes during the 6 months before
inclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every
4 weeks for 28 weeks. Angioedema-related QoL, skin-related QoL impairment, and
psychological well-being were assessed.
Results: Ninety-one patients were randomized and 68 (omalizumab, n = 35; placebo,
n = 33) completed the 28-week treatment period. At baseline, the mean (SD) total
Angioedema QoL (AE-QoL; 56.2 [18.7] and 59.9 [19.2]) and Dermatology Life Quality
Index (DLQI; 14.6 [5.7] and 16.6 [7.3]) score were high in the omalizumab and placebo
group, respectively. At Week 4 (after the first treatment), the least squares mean dif-
ference in the AE-QoL and DLQI score between groups was 17.6 (P < .001) and
7.2 (P < .001), respectively. Significant QoL improvements in the omalizumab vs pla-
cebo groups continued until Week 28, but returned to placebo levels at the follow-up
visit. The mean (SD) baseline 5-item World Health Organization Well-being Index was
10.0 (5.5, omalizumab) and 7.7 (5.3, placebo), which increased above the depression
threshold (<13) from Week 4 and throughout with omalizumab but not placebo treat-
ment. Compared to placebo, omalizumab was also associated with decreased fear of
suffocation due to angioedema.
Conclusions: Our findings support omalizumab treatment in patients with severe
H1-antihistamine-refractory CSU with angioedema.
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1 | INTRODUCTION
Chronic spontaneous urticaria (CSU) involves the repeated occur-
rence of wheals (hives), angioedema, or both for more than 6 weeks,
without any specific external trigger.1,2 Angioedema is an important
symptom associated with CSU; it is characterized by a sudden swel-
ling of the dermis, subcutaneous tissue, mucosa, and/or submucosa,
which usually occurs around the eyes, lips and mouth, arms and legs,
genitalia, or hands.3 Approximately 33%-67% of CSU patients
reportedly experience wheals and angioedema, and 1%-13% report-
edly experience only angioedema.4 Furthermore, recent data from
the observational AWARE study indicate that 46.1% of German CSU
patients, who remained symptomatic despite treatment with at least
the approved dose of H1-antihistamines, had both, wheals and
angioedema, while 2.9% exclusively had angioedema.5 Angioedema
is a major driver of quality-of-life (QoL) impairment in patients with
CSU.6 Owing to the unpredictable development of disfigurement
and/or functional impairment, angioedema episodes can have a sig-
nificant impact on daily activities and social interactions in CSU
patients.4 Furthermore, patients report missing work or school owing
to their angioedema.
Omalizumab is approved as an add-on therapy in patients with
CSU refractory to H1-antihistamines.
7 Several randomized con-
trolled trials (RCTs) have shown that omalizumab effectively con-
trols the symptoms of CSU (itching and wheals)8-14 and improves
the QoL in CSU patients.8-16 We recently reported that subcuta-
neous omalizumab (300 mg) also reduces the frequency and sever-
ity of angioedema in H1-antihistamine-refractory CSU patients.
4
Furthermore, omalizumab reduced QoL impairment in the same
patient cohort,4 as assessed using the validated CSU-specific QoL
Questionnaire (CU-Q2oL). However, a number of questions remain
unanswered for H1-antihistamine-refractory CSU patients with
angioedema: (1) Are specific domains of QoL and psychological
well-being more severely affected than other aspects at baseline?
(2) Do angioedema-related QoL scores and psychological well-being
improve over the course of omalizumab treatment? and (3) Are
improvements in symptom severity correlated with changes in
QoL?
Here, we present results from the X-ACT (Xolair Effects on
Angioedema in Chronic Spontaneous Urticaria Treatment) study, to
bridge the gaps in the knowledge on angioedema-related QoL
impairment and improvement with omalizumab treatment.
2 | METHODS
2.1 | X-ACT study design
X-ACT was a randomized, double-blind, placebo-controlled, multicen-
ter, phase III study that has previously been described in detail.4 The
trial was conducted between January 2013 and May 2014 in 24
centers across Germany. Briefly, the study was divided into a 2-
week screening period, a 28-week double-blind treatment phase in
which patients were randomized (1:1) to receive subcutaneous
injections of omalizumab 300 mg or placebo every 4 weeks from
baseline (Week 0) until Week 24, and an 8-week follow-up phase
(Figure 1). The study protocol was reviewed by an Independent
Ethics Committee or Institutional Review Board for all study centers
in Germany. All patients provided written informed consent prior to
study initiation (ClinicalTrials.gov number: NCT01723072; EudraCT
number: 2011-004254-25).
2.2 | Study patients
Male and female CSU patients aged 18-75 years with a history of
angioedema (at least 4 episodes within the last 6 months before
study enrollment), who remain symptomatic despite the use of two-
to-four times the recommended dose of second-generation H1-anti-
histamine treatment, with an urticaria activity score (UAS) over
7 days (UAS7) of ≥14 and a CU-Q2oL score of ≥30 at baseline were
included in the study. Patients underwent a clinical examination by
an experienced physician, and a thorough history was taken; the
presence of any form of chronic inducible urticaria was explicitly
checked for, including delayed pressure urticaria which can be mis-
taken for angioedema. Patients were excluded from the study if they
had non-urticaria-associated angioedema (eg, low C1-inhibitor levels),
serious psychological disturbance, metabolic and pathological condi-
tions, history of malignancy, hypersensitivity to omalizumab, or had
received treatment with omalizumab within the previous 6 months.
2.3 | Study objectives and endpoints
The primary objective of the X-ACT trial was to evaluate the efficacy
of once-monthly add-on injections of omalizumab (300 mg; subcuta-
neously for 28 weeks) compared to placebo on the QoL of CSU
patients with angioedema refractory to H1-antihistamines (CU-
Q2oL).
4 Key secondary endpoints included changes in angioedema
disease activity, as well as angioedema-specific and overall skin-
related QoL impairment following omalizumab treatment.
2.4 | Patient-reported outcomes: disease activity,
QoL, and psychological well-being
The Angioedema Activity Score (AAS) was completed by patients on
a daily basis and recorded in a paper-based symptom diary. The AAS
is a validated questionnaire that consists of an opening question
(Have you had a swelling episode in the last 24 h?), followed by the
five specific AAS questions to determine the severity and impact of
the angioedema episode.12 The daily AAS values are added over
7 days and, in the present study, weekly scores were recorded at
every patient visit (baseline/Week 0, and Weeks 4, 8, 12, 16, 20, 24,
28, and 36). Weekly AAS (AAS7) scores range from 0 to 105, with
higher scores indicative of a higher disease activity.
The Angioedema Quality of Life (AE-QoL) is a validated, angioe-
dema-specific 17-item questionnaire that includes four subdomains:
functioning, fatigue/mood, fears/shame, and food. Each item is
answered on a 5-point Likert scale (0 = not important to 4 = very
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important). The results of all the answered questions are summed up
and transferred to a scale ranging from 0 to 100, with higher scores
indicative of a higher QoL impairment.17,18
Two separate questions related to patients’ fear of a life-threa-
tening angioedema episode were included to explore this potential
complication further: (1) Were you afraid of a life-threatening swel-
ling episode? and (2) Were you afraid of suffocating due to the swel-
ling episode? Questions were answered on a 5-point Likert scale
(0 = never to 4 = very often), with higher scores indicative of an
increased fear of a life-threatening angioedema attack. The results of
both questions were analyzed descriptively by visit, and missing
scores were not replaced.
The Dermatology Life Quality Index (DLQI) is a validated, derma-
tology-specific 10-item questionnaire with six subheadings: symp-
toms and feelings, daily activities, leisure, work and school, personal
relationships, and treatment. The DLQI score ranges between 0 and
30, with higher scores indicative of a higher QoL impairment.19
The 5-item World Health Organization Well-being Index (WHO-
5) is a validated, 5-item, positively-worded questionnaire that mea-
sures patient well-being in terms of mood, vitality, and general inter-
ests. The maximum score is 25, and values lower than 13 are
indicative of signs of depression.20
2.5 | Statistical analysis
Subjects were analyzed according to the treatment to which they
were randomized. All results presented here are based on the full
analysis set (FAS; all randomized subjects who received at least one
dose of the study drug). The secondary endpoint analysis was per-
formed by comparing the two treatments with respect to change in
AE-QoL and DLQI scores using an analysis of covariance (ANCOVA)
model with treatment and center as factors and baseline score as a
covariate. The analysis was conducted in the FAS using the last
observation carried forward (LOCF) and for the DLQI and observed
values for the AE-QoL questionnaire. Data for the omalizumab treat-
ment group were compared to those of the placebo group. The
AAS7 was analyzed analogously to the AE-QoL and DLQI as a mean
difference from baseline (Visit 2) to Week 28 (Visit 9) in an
ANCOVA analysis conducted on the FAS using observed cases. The
WHO-5 and the questions on fear of a life-threatening angioedema
episode were regarded as exploratory questionnaires. Pearson corre-
lation coefficients were computed to explore the correlations
between different endpoints.
3 | RESULTS
A total of 91 CSU patients were randomized to one of two groups:
omalizumab (n = 44) or placebo (n = 47; Figure 1). On average,
patients experienced 2.7 and 3.4 angioedema-burdened days during
the screening phase (Week 2 to Week 1) in the omalizumab and
placebo group, respectively. The mean (SD) AAS7 scores at baseline
were also high in both the omalizumab (22.5 [20.6]) and placebo
(28.1 [24.1]) groups indicating that angioedema activity was high
(Table 1). Baseline demographics and disease characteristics have
been reported in detail previously.4
The mean (SD) AE-QoL total scores (omalizumab 300 mg:
56.2 [18.7]; placebo: 59.9 [19.2]) were also high at baseline,
reflecting poor QoL in these patients (Table 1). The most
severely affected subdomains of the AE-QoL were fears/shame,
fatigue/mood, and functioning (Table 2). The subdomain of food
was less severely affected, but still indicated impairment in both
groups. The mean DLQI total scores (omalizumab: 14.6 [5.7]; pla-
cebo: 16.6 [7.3]) also reflected poor QoL. The most severely
affected subdomains of the DLQI score were symptoms and feel-
ings, daily activities, and leisure. Total and subdomain scores
were comparable for the omalizumab and placebo groups at
baseline (Tables 1 and 2).
F IGURE 1 X-ACT study design. N = 68
patients (omalizumab, n = 35; placebo,
n = 33) completed the 28-week treatment
period. Patients received omalizumab or
placebo as add-on therapy to the
screening period-defined up-dosed H1-
antihistamine treatment
TABLE 1 Baseline values of health-related QoL impairment,







Total score 22.5 (20.6) 28.1 (24.1)
Angioedema-burdened days 2.7 (2.34) 3.5 (2.35)
AE-QoL
Total score 56.2 (18.7) 59.9 (19.2)
DLQI
Total score 14.6 (5.7) 16.6 (7.3)
WHO-5 index
Total score 10.0 (5.5) 7.7 (5.3)
Data are presented as mean (SD). AAS, Angioedema Activity Score; AE-
QoL, Angioedema Quality of Life Questionnaire; DLQI, Dermatology Life
Quality Index; QoL, quality of life; SD, standard deviation; WHO-5, 5-
item World Health Organization Well-being Index.
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3.1 | AE-QoL and DLQI scores improve rapidly with
omalizumab treatment
The AE-QoL and DLQI scores decreased rapidly following initiation
of omalizumab treatment, and the improvements increased further
throughout the treatment period (Figure 2A and B). The least
squares (LS) mean difference in the AE-QoL total scores between
groups was 17.6 (P < .001) at Week 4, 26.0 (P < .001) at Week
12, 16.3 (P = .006) at Week 20, and 22.7 (P < .001) at Week 28.
The LS mean difference in DLQI scores between groups was 7.2
(P < .001) at Week 4, 8.0 (P < .001) at Week 12, 5.8 (P < .001)
at Week 20, and 6.1 (P < .001) at Week 28. The mean (SD) total
AE-QoL (omalizumab: 27.7 [22.9]; placebo: 36.2 [24.4]) and DLQI
(omalizumab, 7.8 [7.8]; placebo, 11.2 [8.6]) scores approached pla-
cebo levels at the follow-up visit 12 weeks after the last omalizumab
injection.
The mean AAS7 scores decreased rapidly following omalizumab
treatment initiation, with significant differences observed as early as
Week 4 (Visit 3).4 AAS7 scores decreased further throughout the
omalizumab treatment period; the LS mean difference between
groups was 15.6 (P < .001) at Week 4, 14.1 (P = .002) at Week
12, 7.0 (P = .056) at Week 20, and 9.8 (P = .036) at Week 28.
Following discontinuation of omalizumab (Week 36), the mean (SD)
AAS7 scores increased to placebo levels (omalizumab, 10.2 [19.6];
placebo, 9.8 [12.0]).
Analyses of the AE-QoL subdomain scores showed that, after
4 weeks of treatment, patients in the omalizumab group had signifi-
cantly greater mean improvements from baseline in three subdo-
mains of the AE-QoL compared to the placebo group as follows:
functioning, 33.1 vs 6.3 (P < .001); fatigue/mood, 24.3 vs
12.6 (P = .030); fear/shame, 29.3 vs 12.3 (P = .007). The AE-
QoL food subdomain mean scores improved in both the omalizumab
and the placebo arms of the study (10.2 vs 6.3 [P = .444]). At
Week 28, the mean change from baseline for the DLQI subdomains
in the omalizumab treatment and placebo groups were as follows:
symptoms and feelings, 3.2 vs. 1.9 (P = .005); daily activities,
2.5 vs. 1.9 (P = .208); leisure, 2.3 vs. 2.4 (P = .833); work and
school, 1.0 vs. 0.8 (P = .509); personal relationship, 2.1 vs. 1.8
(P = .500); and treatment, 0.6 vs. 0.8 (P = .412) (Table 2).
3.2 | Fear of life-threatening angioedema is
reduced during omalizumab treatment
At baseline, when we asked patients whether they were afraid of a
life-threatening swelling episode, 66.7% responded “occasionally,”
“often,” or “very often.” Similarly, 48.9% of patients were “occasion-
ally” to “very often” afraid that “they could suffocate due to a swel-
ling episode,” emphasizing the gravity of the burden of disease these
patients experience (Table 2).
After 28 weeks of omalizumab treatment, only a minority of
patients still experienced these fears: 13.6% were “occasionally” to
“very often” afraid of life-threatening swelling compared to 41.7% in
the placebo group, and 4.5% were “occasionally” to “very often”
F IGURE 2 LS mean changes in (A) AE-QoL total scores (observed
values), (B) DLQI scores (LOCF), and (C) weekly AAS scores (zero
was imputed for missing AAS day sum scores) from baseline. The
values represented are the LS mean change from baseline for the
FAS, using analysis of covariance. *indicates P < .05, **indicates
P < .01, and ***indicates P < .001 (LS mean for difference between
treatment groups; ANCOVA model). The black triangles indicate
omalizumab/placebo administration (Weeks 4, 8, 12, 16, 20, and 24).
AAS, Angioedema Activity Score; AE-QoL, Angioedema Quality of
Life Questionnaire; ANCOVA, analysis of covariance; DLQI,
Dermatology Life Quality Index; FAS, full analysis set; LOCF, last
observation carried forward; LS, least square
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afraid of suffocating owing to a swelling episode compared to
25.1% in the placebo group. Reduced fear of a life-threatening
angioedema episode was evident as early as 4 weeks after starting
omalizumab treatment but increased upon discontinuation of treat-
ment, that is, at Week 28, 63.6% of patients were “never” afraid of
life-threatening angioedema episodes compared to 29.2% in the pla-
cebo group, and during the follow-up period, these proportions were
37.5% and 35.7% in the omalizumab and placebo groups, respec-
tively (Table 2).
3.3 | General psychological well-being improves
with omalizumab treatment
At baseline, the WHO-5 score indicated a signal for depression in
both groups (mean score below the depression threshold of 13;
Table 1); however, only 4.5% of patients in the omalizumab group
and 8.5% of patients in the placebo group had a previous or current
diagnosis of depression. In the omalizumab group, the mean (SD)
WHO-5 score was 10.0 (5.5) at baseline and increased above the
depression threshold to 18.6 (5.1) by the end of the treatment per-
iod. The corresponding results in the placebo group were 7.7 (5.3) at
baseline and 11.5 (5.8) at Week 28 (LS mean difference between
groups at Week 28, P < .001; Figure 3).
At Week 28, 82.4% of the omalizumab-treated patients showed
no signal for depression, that is, a WHO-5 score of ≥13 points, com-
pared to only 41.9% of patients in the placebo group. The probabil-
ity of reaching the critical threshold (score 13) at the end of the
treatment period was 5.6 times higher (odds ratio [OR]: 5.55, 95%
confidence interval [CI]: 1.7-18.2) in the omalizumab group com-
pared to the placebo group (P = .005, Wald test). Furthermore,
impaired psychological well-being, assessed using the WHO-5, corre-
lated well (Pearson correlation coefficient) with the markedly
impaired QoL scores at baseline (AE-QoL, 0.618 [P < .001]; DLQI,
0.614 [P < .001]) and at Week 28 (AE-QoL, 0.666 [P < .001];
DLQI, 0.591 [P < .001]).
3.4 | Improvement in angioedema symptoms is
correlated with health-related QoL
Angioedema-related QoL improved with improved AAS scores.
Changes in total AE-QoL and AAS7 scores from baseline were signif-
icantly correlated at Week 12 (0.526, P < .001) and at Week 28
(0.501, P < .001). Furthermore, changes in weekly AAS scores corre-
lated with changes in DLQI and WHO-5 scores at Week 12 (0.518,
P < .001 and 0.319, P = .007, respectively) and Week 28 (0.546,
P < .001 and .321, P = .009, respectively).
Subgroup analyses revealed that female patients had higher AE-
QoL scores at baseline compared to male patients (P = .001;
Table 3). Although baseline AE-QoL impairment was significantly
higher in females compared to males, there was no significant influ-
ence of any factors investigated (age [P = .694], sex [P = .757], dis-
ease duration [P = .815], or angioedema activity [baseline AAS7;
P = .516]) on the response to treatment (Table 3).
4 | DISCUSSION
To our knowledge, X-ACT is the first study designed to investigate
the effects of omalizumab 300 mg treatment on the impact of
angioedema on QoL in patients with moderate-to-severe CSU. Our
findings show that antihistamine-refractory CSU patients with
angioedema experience significant QoL impairment, general psycho-
logical impairment, and fear of life-threatening angioedema episodes
at baseline, all of which rapidly reduced following the initiation of
omalizumab treatment.
We have previously reported that omalizumab treatment signifi-
cantly reduced the disease activity (AAS7), improved CSU-related
QoL, and reduced number of angioedema-burdened days per week
and size of individual swelling episodes.4 We also observed a rapid
improvement in angioedema-related QoL and psychological well-
being as well as reduced angioedema-related fears, which continued
to improve over the course of omalizumab treatment. The rapid
improvements in symptoms and QoL observed in these CSU patients
are consistent with previous CSU trials, where omalizumab led to a
rapid decrease in CSU symptoms and QoL impairment.12,13,21 In
addition, a recent analysis of three phase 3 studies showed that
omalizumab 300 mg significantly improved total DLQI scores vs. pla-
cebo, with a mean decrease from baseline to Week 12 of 10.3 vs.
6.1 (P < .0001) in ASTERIA I, 10.2 vs. 6.1 (P = .0004) in
ASTERIA II and 9.7 vs. 5.1 (P < .0001) in GLACIAL.22 The propor-
tion of patients in whom changes in mean total DLQI score from
baseline to Week 12 reached a minimal clinically important differ-
ence (MCID) of ≥4 was 74.1%, 76.0%, and 77.2% in ASTERIA I, II,
and GLACIAL, respectively (P < .01; all studies).22 Clinical observa-
tions indicate that the onset of omalizumab effect may be even ear-
lier than 4 weeks, but data from controlled clinical trials are missing.
Improvements in the AE-QoL total scores in this study indicate a
clinically meaningful benefit with omalizumab treatment; mean
improvements were approximately 6.5 times higher than the
F IGURE 3 WHO-5 scores at baseline, Week 4, Week 12, Week
28, and the follow-up visit at Week 36. A score <13 indicates
that the patient is showing signs of depression. Data are presented
as mean (SD) WHO-5 scores (observed cases). SD, standard
deviation; WHO-5, 5-item World Health Organization Well-being
Index
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previously reported MCID of the total AE-QoL score (6 points)18
and correlated well with improved AAS7 scores. Moreover, the
change in DLQI score was also above the previously defined MCID
threshold of 2.2 to 3.1 points.23 Interestingly, these rapid QoL
improvements were not only visible in the total score but also in all
but one of the AE-QoL subdomain scores. The rapid decreases in
the AE-QoL subdomain scores indicate that patient’s QoL is
restored, their functioning in daily life and work life returns to a nor-
mal level, they overcome their sleeping problems and depressive
mood, as well as their fears and embarrassment associated with the
swellings. This observation surpassed our expectations, as it was
thought that some subdomains, such as fear/shame, could have been
less responsive to omalizumab treatment, or could have responded
more slowly. The rapid reduction in QoL appears to be directly asso-
ciated with the rapid reduction in the frequency and severity of
angioedema. In line with this and as reported previously, symptoms
began to reappear, and QoL scores worsened again to placebo levels
following omalizumab discontinuation.4,11-13
Angioedema can be mediated by histamine or bradykinin. Heredi-
tary angioedema (HAE)12 is bradykinin-mediated and usually develops
over the course of several hours, whereas in CSU, angioedema is his-
tamine-mediated and develops rapidly.24 For HAE patients, angioe-
dema episodes can range from a minor inconvenience to life-
threatening episodes, with a mortality rate of approximately 30% in the
case of laryngeal edema.25 In contrast, angioedema is not considered
life-threatening for CSU patients. Despite this, the majority of patients
in the X-ACT trial reported angioedema-related fears at baseline, and
although no patient experienced a truly life-threatening swelling epi-
sode, they still reported fears of suffocation and of life-threatening
symptoms. During omalizumab treatment, symptom-related fears
decreased compared to the placebo group, but these fears reappeared
following omalizumab discontinuation; this further supports the benefit
of omalizumab in CSU patients with antihistamine-refractory angioe-
dema. Patient education and appropriate treatment are required to
reduce the fears associated with angioedema in CSU patients. Further-
more, the rapid symptom improvement and reduced angioedema-asso-
ciated fears observed with omalizumab treatment could reduce health-
resource utilization, such as the number of patient visits to the emer-
gency department, as well as reducing work productivity loss and/or
sick leave duration owing to angioedema.26
Chronic spontaneous urticaria patients are reported to have an
increased risk of psychiatric comorbidities, including depression.27-29
In patients with other chronic diseases, depression has been associ-
ated with decreased treatment adherence, sleep disturbance, and
negative perception of the illness.30 Here, the mean WHO-5 score
was <13 for both treatment groups at baseline, indicating that
depression may be present in these patients and that CSU with
angioedema must not be classified as a trivial disease or just a cos-
metic problem. Following appropriate treatment of CSU-related
symptoms with omalizumab, approximately 80% of patients showed
no sign of depression (≥13 points in the WHO-5) compared with
approximately 40% in the placebo group. Thus, omalizumab treat-
ment is not only associated with improvement in the disease condi-
tion but also the psychological symptoms associated with CSU.
These results suggest that the psychological symptoms observed in
CSU patients may be a reaction to the dermatological symptoms
experienced; however, further research is required to confirm this.
4.1 | Limitations
This study only considered CSU patients with wheals and angioe-
dema, although there are CSU patients with angioedema without/
TABLE 3 AE-QoL total scores by subgroups at baseline and at Week 28 (observed values for the FAS)
Baseline Week 28
Omalizumab Placebo Omalizumab Placebo
Overall 56.2 (18.69; n = 44) 59.9 (19.24; n = 47) 14.1 (14.82; n = 34) 38.1 (23.56; n = 25)
Sex
Male 43.6 (19.49; n = 14) 54.0 (12.56; n = 14) 12.1 (14.74; n = 10) 31.3 (22.84; n = 7)
Femalea 62.0 (15.35; n = 30) 62.5 (21.12; n = 33) 15.0 (15.08; n = 24) 40.8 (23.93; n = 18)
Age class
<40 y 59.1 (15.99; n = 14) 57.1 (15.97; n = 22) 13.4 (13.31; n = 10) 41.4 (29.11; n = 7)
≥40 y 54.8 (19.93; n = 30) 62.5 (21.73; n = 25) 14.4 (15.67; n = 24) 36.8 (21.87; n = 18)
Disease duration
<2 y 51.6 (19.19; n = 13) 52.9 (19.19; n = 13) 12.9 (9.53; n = 10) 33.8 (14.9; n = 7)
≥2 y 58.1 (18.44; n = 31) 62.6 (18.85; n = 34) 14.6 (16.69; n = 24) 39.8 (26.35; n = 18)
Disease severity (AAS)
<20 49.3 (20.1; n = 25) 56.4 (17.66; n = 22) 15.8 (17.1; n = 19) 30.9 (20.65; n = 12)
≥20 65.2 (11.97; n = 19) 63.1 (20.36; n = 25) 12.0 (11.52; n = 15) 44.8 (24.86; n = 13)
AAS, Angioedema Activity Score; AE-QoL, Angioedema Quality of Life Questionnaire; FAS, full analysis set; SD, standard deviation.
Data are presented as mean (SD; n).
aindicates P < .001 (t test; Satterthwaite method) comparing mean (SD) AE-QoL total score at baseline between male (48.8 [16.94]) and female (62.3
[18.45]) patients.
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with almost no wheals, who require adequate therapy. Based on the
rapid improvement in angioedema activity and angioedema-related
QoL observed in the X-ACT patient population, CSU patients with-
out wheals would also likely benefit from omalizumab treatment;
however, further studies are warranted in this specific patient popu-
lation. Furthermore, only adult patients were enrolled in the X-ACT
study; therefore, it is unclear whether these results can be extrapo-
lated to children and adolescents with CSU. Finally, the use of con-
comitant psychological medications was permitted in the X-ACT
study and their use may be regarded as a surrogate for the presence
of mild psychiatric/psychological comorbidities that may negatively
impact QoL and psychological well-being. However, their use was
low and was comparable between the omalizumab (n = 4) and pla-
cebo (n = 5) groups. Thus, the expected impact on the outcome
parameters is low.
5 | CONCLUSIONS
Patients with moderate-to-severe CSU with angioedema that is
refractory to high doses of H1-antihistamines have impaired QoL,
fear of suffocation due to swelling episodes, and impaired psycho-
logical well-being, including an increased risk for signs of depression.
This study revealed that omalizumab is a highly effective treatment
for this patient cohort and is associated with a marked and rapid
improvement in angioedema symptoms, angioedema-related QoL,
symptom-related fears, and psychological well-being. Based on these
findings, we recommend that omalizumab is prescribed for the treat-
ment of patients with severe H1-antihistamine-refractory CSU with
angioedema.
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